Literature DB >> 15904975

Modulation of the cytokine network in human adult astrocytes by human herpesvirus-6A.

Sonja Meeuwsen1, Carla Persoon-Deen, Malika Bsibsi, Jeffrey J Bajramovic, Rivka Ravid, Leen De Bolle, Johannes M van Noort.   

Abstract

Human herpesvirus-6A (HHV-6A) is a common pathogen whose role in CNS disorders including multiple sclerosis remains controversial. To understand how HHV-6A could influence inflammatory pathways in the CNS, we infected cultured human adult astrocytes and examined the expression of 268 cytokines, chemokines, growth factors and their receptors by gene profiling. HHV-6 infection alone had little effect on the astrocyte gene profile but strongly altered the astrocyte response to proinflammatory cytokines. Under those conditions astrocytes express higher levels of anti-inflammatory mediators including IL-10 and IL-11, chemotactic factors, growth factors and factors controlling type I interferon production. Our data suggest that HHV-6 itself does not evoke a pro-inflammatory response in astrocytes but rather triggers immune modulatory factors in the face of inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15904975     DOI: 10.1016/j.jneuroim.2005.03.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

Review 1.  CD46 plasticity and its inflammatory bias in multiple sclerosis.

Authors:  Siobhan Ni Choileain; Anne L Astier
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-01-26       Impact factor: 4.291

Review 2.  Review part 2: Human herpesvirus-6 in central nervous system diseases.

Authors:  Karen Yao; John R Crawford; Anthony L Komaroff; Dharam V Ablashi; Steven Jacobson
Journal:  J Med Virol       Date:  2010-10       Impact factor: 2.327

3.  Herpesvirus and neurological manifestations in patients with severe coronavirus disease.

Authors:  Vanessa Cristine de Souza Carneiro; Soniza Vieira Alves-Leon; Dmitry José de Santana Sarmento; Wagner Luis da Costa Nunes Pimentel Coelho; Otacilio da Cruz Moreira; Andreza Lemos Salvio; Carlos Henrique Ferreira Ramos; Carlos Henrique Ferreira Ramos Filho; Carla Augusta Barreto Marques; João Paulo da Costa Gonçalves; Luciane Almeida Amado Leon; Vanessa Salete de Paula
Journal:  Virol J       Date:  2022-06-08       Impact factor: 5.913

4.  Human herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9.

Authors:  Joséphine M Reynaud; Jean-François Jégou; Jérémy C Welsch; Branka Horvat
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

Review 5.  Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation.

Authors:  Anthony L Komaroff; Philip E Pellett; Steven Jacobson
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

6.  Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis.

Authors:  Karen Yao; Somayeh Honarmand; Alex Espinosa; Nahid Akhyani; Carol Glaser; Steven Jacobson
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

7.  Human Herpesvirus 6A U4 Inhibits Proteasomal Degradation of the Amyloid Precursor Protein.

Authors:  Tian Tang; Junli Jia; Emanuela Garbarino; Luyao Chen; Jingjing Ma; Peipei Li; Xiangjun Chen; Lily Wang; Yiqun Wen; Yuhang Wang; Lingyun Li; Kun Yao; Huamin Tang
Journal:  J Virol       Date:  2021-12-08       Impact factor: 6.549

Review 8.  Co-infections and Pathogenesis of KSHV-Associated Malignancies.

Authors:  Suhani Thakker; Subhash C Verma
Journal:  Front Microbiol       Date:  2016-02-15       Impact factor: 5.640

Review 9.  Balancing the immune response in the brain: IL-10 and its regulation.

Authors:  Diogo Lobo-Silva; Guilhermina M Carriche; A Gil Castro; Susana Roque; Margarida Saraiva
Journal:  J Neuroinflammation       Date:  2016-11-24       Impact factor: 8.322

Review 10.  Multiple sclerosis: an example of pathogenic viral interaction?

Authors:  Walter Fierz
Journal:  Virol J       Date:  2017-02-28       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.